3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone has been researched along with Alloxan Diabetes in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Anderson, S; Cohen, DM; Komers, R; Lindsley, JN; Oyama, TT; Tian, W | 1 |
1 other study(ies) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and Alloxan Diabetes
Article | Year |
---|---|
Effects of cyclooxygenase-2 (COX-2) inhibition on plasma and renal renin in diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diabetes Mellitus, Experimental; Drug Interactions; Enalapril; Furans; Isoenzymes; Kidney; Male; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2002 |